Free Trial
NASDAQ:CMMB

Chemomab Therapeutics Q4 2025 Earnings Results & Report

Chemomab Therapeutics logo
$1.53 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.54 +0.01 (+0.98%)
As of 11/13/2026 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Chemomab Therapeutics missed analyst earnings expectations in its Q4 2025 results, released March 19, 2026. The company reported EPS of -$0.24 versus the -$0.20 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Chemomab Therapeutics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Chemomab Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chemomab Therapeutics Q4 2025 Earnings FAQ

Chemomab Therapeutics (NASDAQ:CMMB) reported earnings of -$0.24 per share for Q4 2025, missing the consensus estimate of -$0.20. The report was announced on Thursday, March 19, 2026.

Chemomab Therapeutics Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Chemomab Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring.

The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis.

Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics. Its leadership has included co-founder Yuval Cohen as chief executive officer.

View Chemomab Therapeutics Profile